All Programs

Use the tool below to view all available Global Oncology Academy Series

Assessing Efficacy and Cost of Blood-Based Tests for Colorectal Cancer
Assessing Efficacy and Cost of Blood-Based Tests for Colorectal Cancer
Clinician's Roundtable
Assessing Efficacy and Cost of Blood-Based Tests for Colorectal Cancer
- Charles Turck, PharmD, BCPS, BCCCP
- Samuel Muench, MD
Optimizing Nivolumab in NSCLC: Implications for Cost, Access, and Outcomes
Optimizing Nivolumab in NSCLC: Implications for Cost, Access, and Outcomes
Project Oncology®
Optimizing Nivolumab in NSCLC: Implications for Cost, Access, and Outcomes
- Aline Fares, MD
Studying Carboplatin-Paclitaxel + Retifanlimab for Squamous Cell Carcinoma of the Anal Canal
Studying Carboplatin-Paclitaxel + Retifanlimab for Squamous Cell Carcinoma of the Anal Canal
Project Oncology®
Studying Carboplatin-Paclitaxel + Retifanlimab for Squamous Cell Carcinoma of the Anal Canal
- Charles Turck, PharmD, BCPS, BCCCP
- Richard Kim, MD
Uncovering Unmet Needs in Squamous Cell Carcinoma of the Anal Canal Care
Uncovering Unmet Needs in Squamous Cell Carcinoma of the Anal Canal Care
Project Oncology®
Uncovering Unmet Needs in Squamous Cell Carcinoma of the Anal Canal Care
- Richard Kim, MD
Bringing Cancer Care Home: How Subcutaneous Immunotherapy Can Help Ease the Burden
Bringing Cancer Care Home: How Subcutaneous Immunotherapy Can Help Ease the Burden
Project Oncology®
Bringing Cancer Care Home: How Subcutaneous Immunotherapy Can Help Ease the Burden
- Jorge Nieva, MD
Early-Onset Endometrial Cancer: Bridging the Gap Between Age and Outcome
Early-Onset Endometrial Cancer: Bridging the Gap Between Age and Outcome
Project Oncology®
Early-Onset Endometrial Cancer: Bridging the Gap Between Age and Outcome
Investigating At-Home Subcutaneous Atezolizumab for NSCLC: An Ongoing Study
Investigating At-Home Subcutaneous Atezolizumab for NSCLC: An Ongoing Study
Project Oncology®
Investigating At-Home Subcutaneous Atezolizumab for NSCLC: An Ongoing Study
- Jorge Nieva, MD
Overall Survival with Neoadjuvant Therapy in HNSCC: Examining Real-World Data
Overall Survival with Neoadjuvant Therapy in HNSCC: Examining Real-World Data
Project Oncology®
Overall Survival with Neoadjuvant Therapy in HNSCC: Examining Real-World Data
- Vanessa Helou, MD
Stratifying ICI-P Risk in Non-Small Cell Lung Cancer with Genetic and Radiographic Markers
Stratifying ICI-P Risk in Non-Small Cell Lung Cancer with Genetic and Radiographic Markers
Project Oncology®
Stratifying ICI-P Risk in Non-Small Cell Lung Cancer with Genetic and Radiographic Markers
Evaluating Dato-DXd for EGFR-Mutated Advanced NSCLC: Data from a Pooled Analysis
Evaluating Dato-DXd for EGFR-Mutated Advanced NSCLC: Data from a Pooled Analysis
Global Oncology Academy
Evaluating Dato-DXd for EGFR-Mutated Advanced NSCLC: Data from a Pooled Analysis
- Jacob Sands, MD
- Elaine Shum, MD
- Estelamari Rodriguez, MD, MPH
Personalizing Prostate Cancer Surveillance: Insights from Canary PASS
Personalizing Prostate Cancer Surveillance: Insights from Canary PASS
Global Oncology Academy
Personalizing Prostate Cancer Surveillance: Insights from Canary PASS
- Lisa Newcomb, PhD
Evolving Strategies in Limited-Stage Small Cell Lung Cancer Management
Evolving Strategies in Limited-Stage Small Cell Lung Cancer Management
Global Oncology Academy
Evolving Strategies in Limited-Stage Small Cell Lung Cancer Management
- Gerard A. Silvestri MD, MS, Master FCCP
- Anurag Singh, MD
- Adam H. Fox, MD, MSc
- Mariam Alexander, MD, PhD
Redefining Risk in Endometrial Cancer: Recurrence Prediction with Machine Learning
Redefining Risk in Endometrial Cancer: Recurrence Prediction with Machine Learning
Project Oncology®
Redefining Risk in Endometrial Cancer: Recurrence Prediction with Machine Learning
Poster Pearl: Axatilimab’s Impact on Fibrosis-Dominant Organs in cGVHD
Poster Pearl: Axatilimab’s Impact on Fibrosis-Dominant Organs in cGVHD
Project Oncology®
Poster Pearl: Axatilimab’s Impact on Fibrosis-Dominant Organs in cGVHD
- Charles Turck, PharmD, BCPS, BCCCP
- Daniel Wolff, MD
ADT Monotherapy for mHSPC: How to Identify the Right Patients
ADT Monotherapy for mHSPC: How to Identify the Right Patients
Global Oncology Academy
ADT Monotherapy for mHSPC: How to Identify the Right Patients
- Daniel J. George, MD
Redefining mHSPC Treatment: From Monotherapy to Triplet Therapy Regimens
Redefining mHSPC Treatment: From Monotherapy to Triplet Therapy Regimens
Global Oncology Academy
Redefining mHSPC Treatment: From Monotherapy to Triplet Therapy Regimens
- Daniel J. George, MD

All Programs

Popular

NEED HELP?

Contact us

NEED HELP?

Contact us

All Programs

Popular

Title

Share on ReachMD

Welcome to the newGlobal Oncology Academy website.

Welcome to the new
Global Oncology Academy website.